Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > News > Ablynx and P&G Extend Agreement

April 18th, 2006

Ablynx and P&G Extend Agreement

Abstract:
Ablynx, the pioneer in the discovery and development of Nanobodies™, has announced that its drug discovery and development alliance with Procter & Gamble Pharmaceuticals, Inc. (P&GP), a subsidiary of The Procter & Gamble Company (NYSE: PG) has been extended to include metabolic disease targets. Through this agreement, Ablynx will use its unique and patent protected Nanobody™ platform to discover and develop drug candidates against targets specified by P&GP.

Source:
Ablynx

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

New blood test rapidly detects signs of pancreatic cancer May 17th, 2018

Elastic microspheres expand understanding of embryonic development and cancer cells May 15th, 2018

Nanomedicine -- Targeting cancer cells with sugars May 14th, 2018

NanoBio Announces Corporate Name Change to BlueWillow Biologics and Closes $10M Series A Financing: Move Reflects Focus on Advancing Several Intranasal Vaccines to Human Studies May 9th, 2018

Announcements

Supersonic waves may help electronics beat the heat May 18th, 2018

New blood test rapidly detects signs of pancreatic cancer May 17th, 2018

Disability Can Be a Superpower in Space Disabled astronauts offer unique solutions to emergencies in space May 17th, 2018

Deeper understanding of quantum chaos may be the key to quantum computers May 16th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project